Do anthracycline-based regimens show activity and safety in patients with MDM2 positive intimal sarcoma?
Patients with MDM2 positive intimal sarcoma (InS), including those with cardiac InS
Systemic treatments including anthracycline-based regimens, gemcitabine, and pazopanib
Anthracycline-based regimens demonstrate clinical activity and appear safe from a cardiac standpoint in patients with MDM2 positive intimal sarcoma, though overall prognosis remains poor.
This retrospective series shows the activity of anthracycline-based regimens in InS. Of note, anthracyclines were used in patients with cardiac InS with no significant cardiac toxicity. The prognosis in patients with InS remains poor, and new active drugs and treatment strategies are needed.
Building similarity graph...
Analyzing shared references across papers
Loading...
Anna Maria Frezza
Tarek Assi
Salvatore Lo Vullo
Cancer
Harvard University
University of Michigan
Cornell University
Building similarity graph...
Analyzing shared references across papers
Loading...
Frezza et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69dc1c562e12f42e21955294 — DOI: https://doi.org/10.1002/cncr.32508